✦ LIBER ✦

Response of Novel Biomarkers to BNP Infusion in Patients with Decompensated Heart Failure: A Multimarker Paradigm

✍ Scribed by Wayne L. Miller; Karen A. Hartman; David O. Hodge; Stacy Hartman; Joachim Struck; Nils G. Morgenthaler; Andreas Bergmann; Allan S. Jaffe

Book ID: 107639446
Publisher: Springer US
Year: 2009
Tongue: English
Weight: 184 KB
Volume: 2
Category: Article
ISSN: 1937-5387
DOI: 10.1007/s12265-009-9121-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monitoring the response to pharmacologic

Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: Is BNP or NT-proBNP a useful assessment tool?

✍ Cynthia M. Balion; Robert S. McKelvie; Sonja Reichert; Pasqualina Santaguida; Ly 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 398 KB

Hemodynamic and clinical effects of a ne

Hemodynamic and clinical effects of a new inotropic agent TA-064 in patients with refractory heart failure due to cardiomyopathy with special reference to dose-response effects

✍ Naoyuki Matsumoto; Kenji Matsumura; Sanae Takahashi; Shinichi Kimata; Koshichiro 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 855 KB

Cenderitide (CD-NP), a novel peptide des

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure

✍ Lisa C Costello-Boerrigter; John A Schirger; Wayne L Miller; Guido Boerrigter; H 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 135 KB

Costello-Boerrigter et al.: Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure.